Sarcoidosis market to reach $69.92 billion by 2030

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Market Size Of The Sarcoidosis Market Expected To Change From 2026 To 2030?

The sarcoidosis market has experienced substantial expansion recently. Projections indicate its value will increase from $34.37 billion in 2025 to $39.72 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 15.6%. Historically, this growth stemmed from factors such as the enduring dependence on corticosteroids for initial treatment, a rise in pulmonary sarcoidosis diagnoses, heightened understanding among specialists like pulmonologists and rheumatologists, progressive advancements in diagnostic imaging, and the restricted access to approved targeted treatments.

The sarcoidosis market is anticipated to experience significant expansion over the coming years. Projections indicate it will reach $69.92 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 15.2%. This projected growth during the forecast period is primarily driven by factors such as the emergence of innovative biologics and immunomodulators, a heightened emphasis on therapeutic alternatives that reduce steroid dependence, the increasing incidence of chronic and systemic sarcoidosis, broader clinical investigations into uncommon inflammatory conditions, and enhanced patient access to specialized medical facilities. Key trends anticipated during this period encompass the expanded off-label application of biologics for sarcoidosis resistant to conventional treatments, a greater focus on managing pulmonary sarcoidosis, the increasing uptake of corticosteroid-reducing treatment plans, enhanced utilization of imaging and biomarker-driven disease surveillance, and the proliferation of clinical trials for new anti-inflammatory agents.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23508&type=smp

Which Key Drivers Are Affecting The Sarcoidosis Market Development?

The sarcoidosis market is anticipated to expand due to the escalating emphasis on personalized medicine. This sophisticated medical treatment strategy customizes therapeutic approaches for individual patients, considering their genetic profile, biomarkers, environmental elements, and lifestyle, thereby guaranteeing more accurate, effective, and targeted interventions. The appeal for personalized medicine is on the rise because it enables treatments to be adapted to an individual’s genetic and biological characteristics, thereby improving efficacy while minimizing adverse effects. In the context of sarcoidosis, personalized medicine customizes treatment by utilizing genetic, biomarker, and clinical profiling to boost effectiveness and lessen side effects. This method improves targeted therapies, addressing the varied nature of the disease and individual patient reactions. As an illustration, in February 2024, the U.S. Food and Drug Administration (FDA), a US-based government regulatory agency, approved 16 new personalized treatments for rare disease patients in 2023, a substantial rise from 6 personalized treatments in 2022, as reported by the Personalized Medicine Coalition, a US-based nonprofit organization. Consequently, the heightened focus on personalized medicine is propelling the expansion of the sarcoidosis market.

How Is Segmentation Applied In The Sarcoidosis Market Segment Analysis?

The sarcoidosis market covered in this report is segmented –

1) By Type: Pulmonary Sarcoidosis, Ocular Sarcoidosis, Neurosarcoidosis, Cardiac Sarcoidosis, Musculoskeletal Sarcoidosis, Cutaneous Sarcoidosis, Renal Sarcoidosis, Hepatic Sarcoidosis, Sarcoidosis Of The Spleen And Bone Marrow

2) By Diagnostic Method: Imaging Technique, Biopsy, Blood Tests

3) By Treatment Type: Corticosteroids, Immunosuppressive Agents, Biologics, Anti-Malarial Drugs

4) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

5) By End Uses: Hospitals And Clinics, Surgical Centers, Diagnostic Centers, Other End Uses

Subsegments:

1) By Pulmonary Sarcoidosis: Acute Pulmonary Sarcoidosis, Chronic Pulmonary Sarcoidosis, Fibrotic Pulmonary Sarcoidosis

2) By Ocular Sarcoidosis: Anterior Uveitis, Posterior Uveitis, Intermediate Uveitis, Panuveitis, Optic Neuropathy

3) By Neurosarcoidosis: Meningeal Neurosarcoidosis, Cranial Nerve Neurosarcoidosis, Peripheral Neuropathy, Spinal Cord Involvement, Hypothalamic-Pituitary Involvement

4) By Cardiac Sarcoidosis: Atrioventricular Block, Ventricular Arrhythmias, Heart Failure, Myocarditis, Sudden Cardiac Arrest

5) By Musculoskeletal Sarcoidosis: Arthritis, Myopathy, Bone Lesions

6) By Cutaneous Sarcoidosis: Lupus Pernio, Erythema Nodosum, Papular Sarcoidosis, Plaque Sarcoidosis, Subcutaneous Sarcoidosis

7) By Renal Sarcoidosis: Granulomatous Interstitial Nephritis, Nephrocalcinosis, Hypercalciuria-Induced Kidney Disease

8) By Hepatic Sarcoidosis: Granulomatous Hepatitis, Portal Hypertension, Hepatic Fibrosis

9) By Sarcoidosis Of The Spleen And Bone Marrow: Splenomegaly, Pancytopenia, Bone Marrow Granulomas

What Trends Are Transforming The Sarcoidosis Market?

Leading firms within the sarcoidosis market are concentrating on creating novel products, like anti-TNFa monoclonal antibody therapy, aiming to present a new biologic treatment that fulfills a vital unaddressed medical need in controlling inflammatory conditions. This anti-tumor necrosis factor-alpha (anti-TNFa) monoclonal antibody therapy functions as a targeted immunotherapy, employing monoclonal antibodies to suppress TNFa, which is a pro-inflammatory cytokine, consequently lessening inflammation and assisting in the management of autoimmune diseases. As an illustration, in November 2023, Xentria, Inc., a US-based clinical-stage biotherapeutics company, reached a significant achievement when its primary candidate, XTMAB-16, was granted Orphan Drug Designation by the European Medicines Agency (EMA). Concurrently, the company began its worldwide clinical study for pulmonary sarcoidosis by enrolling the initial patient. XTMAB-16, a monoclonal antibody designed to target tumor necrosis factor-alpha (TNFa), is under investigation for its capacity to modify inflammatory pathways in pulmonary sarcoidosis, offering a precise alternative to existing corticosteroid-based treatments. This regulatory acknowledgment and clinical progress underscore the increasing global emphasis on innovative biologics for rare diseases, further solidifying Xentria’s dedication to addressing unmet medical requirements with transformative treatment solutions.

Who Are The Companies Participating In The Sarcoidosis Market Environment?

Major companies operating in the sarcoidosis market are Pfizer Inc, F Hoffmann La Roche AG, Merck And Co Inc, AbbVie Inc, Novartis AG, Bristol Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Eli Lilly And Company, Boehringer Ingelheim GmbH, Regeneron Pharmaceuticals Inc, UCB Pharma, Sun Pharmaceutical Industries Ltd, Cipla Ltd, Lupin Limited, Mallinckrodt Pharmaceuticals, Xentria Inc, Molecure SA, Relief Therapeutics Holding AG, Sanofi SA, Amgen Inc, Takeda Pharmaceutical Company Limited, Janssen Pharmaceuticals Inc, Otsuka Pharmaceutical Co Ltd

Get The Full Sarcoidosis Market Report:

https://www.thebusinessresearchcompany.com/report/sarcoidosis-global-market-report

Where Is The Sarcoidosis Market Primarily Concentrated By Region?

Europe was the largest region in the sarcoidosis market in 2025. The regions covered in the sarcoidosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Sarcoidosis Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/sarcoidosis-global-market-report

Browse Through More Reports Similar to the Global Sarcoidosis Market 2026, By The Business Research Company

Mucolipidosis Ii Market Report 2026

https://www.thebusinessresearchcompany.com/report/mucolipidosis-ii-global-market-report

Psoriasis Drugs Market Report

https://www.thebusinessresearchcompany.com/report/psoriasis-drugs-global-market-report

Sarcopenia Treatment Market Report

https://www.thebusinessresearchcompany.com/report/sarcopenia-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795